237 related articles for article (PubMed ID: 24186319)
1. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion.
Lengline E; Beldjord K; Dombret H; Soulier J; Boissel N; Clappier E
Haematologica; 2013 Nov; 98(11):e146-8. PubMed ID: 24186319
[No Abstract] [Full Text] [Related]
2. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.
Weston BW; Hayden MA; Roberts KG; Bowyer S; Hsu J; Fedoriw G; Rao KW; Mullighan CG
J Clin Oncol; 2013 Sep; 31(25):e413-6. PubMed ID: 23835704
[No Abstract] [Full Text] [Related]
3. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications.
Schwab C; Ryan SL; Chilton L; Elliott A; Murray J; Richardson S; Wragg C; Moppett J; Cummins M; Tunstall O; Parker CA; Saha V; Goulden N; Vora A; Moorman AV; Harrison CJ
Blood; 2016 May; 127(18):2214-8. PubMed ID: 26872634
[TBL] [Abstract][Full Text] [Related]
4. B-Cell Precursor-Acute Lymphoblastic Leukemia With EBF1-PDGFRB Fusion Treated With Hematopoietic Stem Cell Transplantation and Imatinib: A Case Report and Literature Review.
Sakurai Y; Sarashina T; Toriumi N; Hatakeyama N; Kanayama T; Imamura T; Osumi T; Ohki K; Kiyokawa N; Azuma H
J Pediatr Hematol Oncol; 2021 Jan; 43(1):e105-e108. PubMed ID: 32068648
[TBL] [Abstract][Full Text] [Related]
5. Effective treatment with imatinib for acute B-lymphoblastic leukaemia with EBF1-PDGFRB fusion.
Horiuchi M; Yoshida M; Yamasaki K; Sakagami R; Aoyama T; Tatsumi N; Tsutsumi M; Nakaya Y; Fuseya H; Yoshimura T; Hayashi Y; Nakao T; Yamane T
Ann Hematol; 2021 May; 100(5):1329-1331. PubMed ID: 33150465
[No Abstract] [Full Text] [Related]
6. PDGFRB disease: right diagnosis to prolong survival.
Passamonti F
Blood; 2014 Jun; 123(23):3526-8. PubMed ID: 24904095
[No Abstract] [Full Text] [Related]
7. Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.
Gosenca D; Kellert B; Metzgeroth G; Haferlach C; Fabarius A; Schwaab J; Kneba M; Scheid C; Töpelt K; Erben P; Haferlach T; Cross NC; Hofmann WK; Seifarth W; Reiter A
Genes Chromosomes Cancer; 2014 May; 53(5):411-21. PubMed ID: 24772479
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with
Fazio F; Barberi W; Cazzaniga G; Fazio G; Messina M; Della Starza I; De Propris MS; Mancini F; Mohamed S; Del Giudice I; Chiaretti S; Moleti ML; Guarini A; Foà R; Testi AM
Leuk Lymphoma; 2020 Feb; 61(2):469-472. PubMed ID: 31558067
[No Abstract] [Full Text] [Related]
9. Long-term imatinib maintenance therapy for adult Philadelphia positive acute lymphoblastic leukemia.
Guillet S; Hirsch P; Marzac C; Mohty M; Marie JP; Legrand O
Leuk Lymphoma; 2014 Nov; 55(11):2646-8. PubMed ID: 24491028
[No Abstract] [Full Text] [Related]
10. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
[TBL] [Abstract][Full Text] [Related]
11. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.
David M; Cross NC; Burgstaller S; Chase A; Curtis C; Dang R; Gardembas M; Goldman JM; Grand F; Hughes G; Huguet F; Lavender L; McArthur GA; Mahon FX; Massimini G; Melo J; Rousselot P; Russell-Jones RJ; Seymour JF; Smith G; Stark A; Waghorn K; Nikolova Z; Apperley JF
Blood; 2007 Jan; 109(1):61-4. PubMed ID: 16960151
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of dasatinib in relapsed CNS, Ph+ ALL that is refractory to radiochemotherapy plus imatinib: a case report.
Gutiérrez-Aguirre H; García-Rodríguez F; Cantú-Rodríguez O; González-Llano O; Jaime-Pérez J; Gómez-Almaguer D
Clin Adv Hematol Oncol; 2011 Nov; 9(11):875-8. PubMed ID: 22252621
[No Abstract] [Full Text] [Related]
13. Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis.
Haroche J; Amoura Z; Charlotte F; Salvatierra J; Wechsler B; Graux C; Brousse N; Piette JC
Blood; 2008 Jun; 111(11):5413-5. PubMed ID: 18502845
[No Abstract] [Full Text] [Related]
14. Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis.
Welsh SJ; Churchman ML; Togni M; Mullighan CG; Hagman J
Leukemia; 2018 Jan; 32(1):38-48. PubMed ID: 28555080
[TBL] [Abstract][Full Text] [Related]
15. Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia.
Winkelmann N; Hidalgo-Curtis C; Waghorn K; Score J; Dickinson H; Jack A; Ali S; Cross NC
Leuk Lymphoma; 2013 Jul; 54(7):1527-31. PubMed ID: 23186533
[TBL] [Abstract][Full Text] [Related]
16. Early diagnosis of EBF1-PDGFRB-positive acute lymphoblastic leukemia.
Ishihara T; Watakabe M; Ochi S; Akisada N; Nogami K
Pediatr Int; 2022 Jan; 64(1):e14955. PubMed ID: 35289450
[No Abstract] [Full Text] [Related]
17. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.
Cheah CY; Burbury K; Apperley JF; Huguet F; Pitini V; Gardembas M; Ross DM; Forrest D; Genet P; Rousselot P; Patton N; Smith G; Dunbar CE; Ito S; Aguiar RC; Odenike O; Gimelfarb A; Cross NC; Seymour JF
Blood; 2014 Jun; 123(23):3574-7. PubMed ID: 24687085
[TBL] [Abstract][Full Text] [Related]
18. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
[TBL] [Abstract][Full Text] [Related]
19. Forced expression of cyclin-dependent kinase 6 confers resistance of pro-B acute lymphocytic leukemia to Gleevec treatment.
Kuo TC; Chavarria-Smith JE; Huang D; Schlissel MS
Mol Cell Biol; 2011 Jul; 31(13):2566-76. PubMed ID: 21536647
[TBL] [Abstract][Full Text] [Related]
20. [Acute lymphoblastic leukemia with EBF1-PDGFRB fusion gene: two cases report and literature review].
Chen YQ; Zheng YZ; Li J; Hua XL; Le SH
Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):69-71. PubMed ID: 36987727
[No Abstract] [Full Text] [Related]
[Next] [New Search]